• Co-Diagnostics advanced its PCR assay development strategy for Bundibugyo virus, the strain driving the current Ebola outbreak in the DRC and Uganda.
• Work is being supported by joint venture CoSara, which could enable faster manufacturing scale-up and deployment in some international markets, subject to regulatory requirements.
• Development plan includes both BDBV-specific assays and pan-Ebola configurations designed to detect multiple ebolavirus species.
• Program also evaluates point-of-care and decentralized workflows for the Co-Dx PCR point-of-care platform, which remains under regulatory review and is not yet for sale.
• WHO reported more than 900 suspected cases and 220 suspected deaths; it declared the outbreak a PHEIC on May 17, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA67526) on May 26, 2026, and is solely responsible for the information contained therein.